Surrozen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRZN research report →
Companywww.surrozen.com
Surrozen, Inc. , a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
- CEO
- Craig C. Parker
- IPO
- 2021
- Employees
- 40
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $197.93M
- P/E
- -0.85
- P/S
- 26.46
- P/B
- -1.04
- EV/EBITDA
- -0.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.13%
- Op Margin
- -573.75%
- Net Margin
- -4571.14%
- ROE
- 309.79%
- ROIC
- -38.03%
Growth & Income
- Revenue
- $3.48M · -67.37%
- Net Income
- $-242,026,000 · -280.76%
- EPS
- $-32.37 · -49.38%
- Op Income
- $-42,092,000
- FCF YoY
- -72.04%
Performance & Tape
- 52W High
- $35.00
- 52W Low
- $7.31
- 50D MA
- $28.90
- 200D MA
- $19.93
- Beta
- 0.59
- Avg Volume
- 102.90K
Get TickerSpark's AI analysis on SRZN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Kutzkey Tim | other | 5,550 |
| May 13, 26 | Rothenberg Mace | other | 5,550 |
| May 13, 26 | WOODHOUSE DAVID J | other | 5,550 |
| May 13, 26 | Haak-Frendscho Mary | other | 5,550 |
| May 13, 26 | CHAI CHRISTOPHER Y | other | 5,550 |
| May 13, 26 | BJERKHOLT ERIC | other | 5,550 |
| May 13, 26 | Berkenblit Anna | other | 5,550 |
| May 1, 26 | Li Yang | other | 4,375 |
| May 4, 26 | Li Yang | sell | 1,584 |
| May 1, 26 | Li Yang | other | 4,375 |
Our SRZN Coverage
We haven't published any research on SRZN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SRZN Report →